$MBOT News

Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting

Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026

Microbot Medical Reports 100% Growth In Revenue, New Clients In Q2

Microbot Medical Signs Letter With Manufacturer Sanmina To Produce Its LIBERTY Single-Use, Remotely Operated Endovascular Robotic System

Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System

Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations

Microbot Medical Inks Agreement With Lovell Government Services To Serve Federal Healthcare Systems

Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System

LUCID CAPITAL MARKETS Initiates Coverage On Microbot Medical with Buy Rating, Announces Price Target of $4

Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System

Microbot Medical Receives Israel's Marketing Clearance For Its LIBERTY System

After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)

Microbot Medical Inc. (MBOT) Shareholder/Analyst Call Transcript

Microbot Medical (NASDAQ:MBOT) Is In A Good Position To Deliver On Growth Plans

Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu

Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026

Watching Microbot Medical; Shares See Volume To The Downside; White Diamond Research Issues Report On Co

Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites